An Open-label, Multicenter, Phase II Study of Chiauranib Capsule in Patients With Advanced or Unresectable Soft Tissue Sarcoma Previously Failed to Standard of Care Treatment
Latest Information Update: 19 Jul 2024
At a glance
- Drugs Ibcasertib (Primary)
- Indications Soft tissue sarcoma
- Focus Therapeutic Use
- Sponsors Chipscreen Biosciences
- 16 Jul 2024 Planned End Date changed from 1 Jun 2024 to 30 Dec 2024.
- 16 Jul 2024 Planned primary completion date changed from 1 Feb 2024 to 30 Dec 2024.
- 16 Jul 2024 Status changed from recruiting to active, no longer recruiting.